Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Incorporation of Genetic Studies in the Kidney Transplant Evaluation Clinic: The Value of a Multidisciplinary Approach
Ters, Mireille El , Prochnow, Carri A., Dean, Patrick G. , Kemppainen, Jennifer L., Cosio, Fernando, Cornell, Lynn D. , Hogan, Marie C. , El Ters, Mireille, Pinto E Vairo, Filippo, Prochnow, Carri, Dean, Patrick, Kemppainen, Jennifer, Lazaridis, Konstantinos, Cornell, Lynn, Cornell, Lynn , Hogan, Marie C , Vairo, Filippo Pinto e , Schinstock, Carrie A. , Lazaridis, Konstantinos , Fervenza, Fernando C. , Amer, Hatem

Mayo Clinic

Transplantation | October 18, 2022 | Volume: 107 | Issue: 4 | Pages: 952-960

10.1097/tp.0000000000004363 | PMID 36253919 Get It

Background. Recent studies identified underlying genetic causes in a proportion of patients with various forms of kidney disease. In particular, genetic testing reclassified some focal segmental glomerulosclerosis (FSGS) cases into collagen type 4 (COL4)-related nephropathy. This knowledge has major implications for counseling prospective transplant recipients about recurrence risk and screening biologically related donors. We describe our experience incorporating genetic testing in our kidney transplant multidisciplinary practice. Methods. Patients’ DNA was analyzed using whole exome sequencing for a comprehensive kidney gene panel encompassing 344 genes associated with kidney diseases and candidate genes highly expressed in the kidney. Results were correlated with phenotype by a multidisciplinary committee of nephrologists, renal pathologists, geneticists, and genetic counselors. Between October 2018 and July 2020, 30 recipient and 5 donor candidates completed testing. Results. Among recipient candidates, 24 (80%) carried the diagnosis of FSGS, 2 (6.7%) tubulointerstitial nephritis, and 1 (3.3%) nephrolithiasis, and 3 (10%) had an unknown cause of kidney disease. The yield for pathogenic/likely pathogenic variants was 43.3%, with majority being COL4 variants (53.8%). Among those with FSGS diagnosis, the yield was 10 of 24 (41.6%), with 29% reclassified into a COL4-related nephropathy. Family history of kidney disease was the only clinical characteristic difference between recipients with positive and negative results (76.9 versus 29.4%; P = 0.025). One of 5 donors tested positive for a pathogenic/likely pathogenic variant and was excluded from donation. Conclusions. We conclude that thoughtful use of genetic testing can be valuable for kidney donor selection and transplant recipient management.
Comparison of Virtual Management of Vulvovaginal Candidiasis to Traditional In-Person Care
Murray, Martha A. , Penza, Kristine L., Furst, Joseph W. , Pecina, Jennifer , Penza, Kristine S , Pecina, Jennifer L.

Mayo Clinic

Telemedicine and e-Health | October 17, 2022 | Volume: 29 | Issue: 5 | Pages: 738-743

10.1089/tmj.2022.0218 | PMID 36251960 Get It

Objective: Compare demographics, treatment, and follow-up rates for patients with complaints of vulvovaginitis suggestive of candida infection evaluated via e-visit, face-to-face (F2F) visits, or nurse-administered phone protocol. Methods: Manual review of 150 vaginitis visits of each visit type (e-visit, F2F, and phone protocol) completed between May 5, 2018 through January 31, 2020 by Mayo Clinic patients residing in Minnesota. Outcomes: Comparison between the three visit types of patient characteristics, treatment rates, type of treatment, follow-up rates, and types of follow-up. Results: Patients utilizing phone visits were significantly older than those seeking care via e-visit ( p < 0.0001) or F2F ( p = 0.001) and were more likely to be treated with oral fluconazole than those treated by e-visit ( p < 0.0001) or F2F ( p < 0.0001) encounters. Patients were significantly less likely to receive fungal directed treatment at a F2F visit than an e-visit ( p < 0.0001) or phone encounter ( p < 0.0001). There was no significant difference in follow-up rates between the three groups. Conclusion: Virtual visits (non-F2F) for suspected vulvovaginal candidiasis are unlikely to result in more follow-up visits than F2F encounters; however, prescriptions for antifungals are significantly higher with virtual visits.
Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors
Thibord, Florian , Klarin, Derek , Brody, Jennifer A. , Chen, Ming‐Huei , Levin, Michael G. , Chasman, Daniel I. , Goode, Ellen L. , Teder‐Laving, Maris , Martínez-Pérez, Ángel , Daian-Bacq, Delphine, Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L. , Nadkarni, Girish N. , Vries, Paul S. de , Wolford, Brooke N. , Pattee, Jack , Brækkan, Sigrid K. , Li‐Gao, Ruifang , Saut, Noémie , Sept, Corriene, Judy, Renae , O’Donnell, Christopher J. , Giulianini, Franco, Boland, Anne , Empana, Jean‐Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Zhou, Wei , Soria, José Manuel , Souto, Juan Carlos , Haessler, Jeffery, Hindberg, Kristian , Bartz, Traci M. , Heckbert, Susan R. , Armasu, Sebastian M. , Brumpton, Ben , Smadja, David M. , Jouven, Xavier , Loos, Ruth J. F. , Sabater‐Lleal, Maria , Pankow, James S. , Reiner, Alex P. , Vlieg, Astrid van Hylckama , Deleuze, Jean-François, Skogholt, Anne Heidi , Emmerich, Joseph , Tang, Weihong , Jackson, Rebecca D. , Hansen, John‐Bjarne , Morange, Pierre‐Emmanuel , Kabrhel, Christopher , Johnson, Andrew D. , Smith, Nicholas L. , Martinez-Perez, Angel , Aïssi, Dylan , Ito, Kaoru , Natarajan, Pradeep , Lutsey, Pamela L , Nadkarni, Girish N , de Vries, Paul S , Wolford, Brooke N , Kooperberg, Charles , Braekkan, Sigrid K , Li-Gao, Ruifang , Saut, Noemie , Germain, Marine , Wiggins, Kerri L , Ko, Darae , O'Donnell, Christopher J , Taylor, Kent D , de Andrade, Mariza , Nøst, Therese H , Boland, Anne , Empana, Jean Philippe , Gilliland, Thomas , Do, Ron , Wang, Xin , Manuel Soria, Jose , Carlos Souto, Juan , Pankratz, Nathan , Rosendaal, Frits R , Turman, Constance , Olaso, Robert , Bartz, Traci M , Lynch, Julie A , Heckbert, Susan R , Brumpton, Ben , Smadja, David M , Komuro, Issei , Clapham, Katharine R , Loos, Ruth J F , Willer, Cristen J , Sabater-Lleal, Maria , Pankow, James S , Reiner, Alexander P , Ridker, Paul M. , Rader, Daniel J , Min Lee, Kyung , Psaty, Bruce M , Rich, Stephen S , Vy, Ha My T , Tang, Weihong , Damrauer, Scott M , Johnson, Andrew D , Smith, Nicholas L , Chasman, Daniel I , Brody, Jennifer A , Hveem, Kristian , Cuéllar-Partida, Gabriel , Kooperberg, Charles , Germain, Marine , Wiggins, Kerri L. , Taylor, Kent D. , Andrade, Mariza de , Koyama, Satoshi , Huffman, Jennifer E. , Pankratz, Nathan , Turman, Constance , Kember, Rachel L. , Lynch, Julie A. , Morelli, Vânia Maris , Deleuze, Jean‐François , Kraft, Peter , Lee, Kyung Min , Psaty, Bruce M. , Suchon, Pierre , Rich, Stephen S. , Trégouët, David‐Alexandre

Mayo Clinic

Circulation | October 17, 2022 | Volume: 146 | Issue: 16 | Pages: 1225-1242

10.1161/circulationaha.122.059675 | PMID 36154123 Get It

Background: Venous thromboembolism (VTE) is a life-threatening vascular event with environmental and genetic determinants. Recent VTE genome-wide association studies (GWAS) meta-analyses involved nearly 30 000 VTE cases and identified up to 40 genetic loci associated with VTE risk, including loci not previously suspected to play a role in hemostasis. The aim of our research was to expand discovery of new genetic loci associated with VTE by using cross-ancestry genomic resources. Methods: We present new cross-ancestry meta-analyzed GWAS results involving up to 81 669 VTE cases from 30 studies, with replication of novel loci in independent populations and loci characterization through in silico genomic interrogations. Results: In our genetic discovery effort that included 55 330 participants with VTE (47 822 European, 6320 African, and 1188 Hispanic ancestry), we identified 48 novel associations, of which 34 were replicated after correction for multiple testing. In our combined discovery-replication analysis (81 669 VTE participants) and ancestry-stratified meta-analyses (European, African, and Hispanic), we identified another 44 novel associations, which are new candidate VTE-associated loci requiring replication. In total, across all GWAS meta-analyses, we identified 135 independent genomic loci significantly associated with VTE risk. A genetic risk score of the significantly associated loci in Europeans identified a 6-fold increase in risk for those in the top 1% of scores compared with those with average scores. We also identified 31 novel transcript associations in transcriptome-wide association studies and 8 novel candidate genes with protein quantitative-trait locus Mendelian randomization analyses. In silico interrogations of hemostasis and hematology traits and a large phenome-wide association analysis of the 135 GWAS loci provided insights to biological pathways contributing to VTE, with some loci contributing to VTE through well-characterized coagulation pathways and others providing new data on the role of hematology traits, particularly platelet function. Many of the replicated loci are outside of known or currently hypothesized pathways to thrombosis. Conclusions: Our cross-ancestry GWAS meta-analyses identified new loci associated with VTE. These findings highlight new pathways to thrombosis and provide novel molecules that may be useful in the development of improved antithrombosis treatments.
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
O'Donoghue, Darragh, Truong, Huong L. , Finnes, Heidi D. , May, Heather P. , Ansell, Stephen M. , Bennani, N. Nora , Habermann, Thomas M. , Inwards, David J. , Johnston, Patrick B. , Khurana, Arushi , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Porrata, Luis F. , Thanarajasingam, Gita , Thompson, Carrie A. , O'Donoghue, Darragh F, Personett, Heather A. , Ansell, Stephen M , Bennani, N Nora , Habermann, Thomas , Micallef, Ivana N , Nowakowski, Grzegorz S , Paludo, Jonas , Thanarajasingam, Gita , Thompson, Carrie A , Villasboas, Jose Caetano , Wang, Yucai , Witzig, T.E. , Leung, Nelson , McDonald, Jennifer S. , Lin, Yi , Paludo, Jonas , Villasboas, José C. , Wang, Yucai , Witzig, Thomas E. , Leung, Nelson

Mayo Clinic

JCO Oncology Practice | October 14, 2022 | Volume: 18 | Issue: 12 | Pages: e1908-e1917

10.1200/op.22.00182 | PMID 36240468 Get It

PURPOSE:High-dose methotrexate (HDMTX; > 500 mg/m2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing MTX toxicity. Our aim was to characterize the incidence of complications and their association with MTX levels.METHODS:A retrospective review of our institutional electronic medical record was conducted to identify patients with lymphoma who received HDMTX between January 1, 2002, and December 31, 2018. We characterized the incidence of acute kidney injury (AKI), intensive care unit (ICU) admission, length of hospital stay (LOS), and 30-day mortality across 48-hour MTX levels. To establish an association between 48-hour MTX levels and the complications listed, we performed chi-square analysis for dichotomous variables and Kruskal-Wallis for nonparametric data. Receiver operator characteristic curve analysis was performed to identify the MTX level where AKI grade ≥ 2 was more likely. Multivariate logistic regression analysis was performed to identify risk factors for this MTX level.RESULTS:We identified 642 patients with 2,804 cycles of HDMTX. The incidence of AKI was 19.1% with AKI grade ≥ 2 making up 21% of cases. Rates of AKI, ICU admission, and 30-day mortality are associated with elevated 48-hour MTX levels. There was a significant increase in median LOS with elevated MTX levels ( P < .001). Receiver operator characteristic curve analysis for AKI grade ≥ 2 demonstrated a 48-hour MTX level threshold of 1.28 μmol/L. Multivariate logistic regression analysis revealed age, male sex, elevated body surface area, higher MTX dose, monotherapy, and first cycle as independent factors.CONCLUSION:Elevated MTX levels are associated with a significant increased rate of AKI, ICU admission, prolonged LOS, and 30-day mortality. Elevated 48-hour MTX levels, particularly > 1.28 μmol/L, should alert clinicians for complications and to initiate measures to reduce MTX levels.
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Benson, Al B. , Al-Hawary, Mahmoud M. , Azad, Nilofer, Chen, Yi‐Jen , Cooper, Harry S. , Deming, Dustin A. , Garrido‐Laguna, Ignacio , Grem, Jean L. , Hecht, J. Randolph, Hoffe, Sarah E. , Hunt, Steven R., Johung, Kimberly L. , Kirilcuk, Natalie, Krishnamurthi, Smitha , Maratt, Jennifer K. , Messersmith, Wells A. , Meyerhardt, Jeffrey A. , Mulcahy, Mary F. , Nurkin, Steven, Overman, Michael J. , Parikh, Aparna, Patel, Hitendra , Shibata, David , Skibber, John M., Sofocleous, Constantinos T. , Stotsky‐Himelfarb, Eden, Tavakkoli, Anna , Willett, Christopher G. , Gregory, Kristina M., Gurski, Lisa A., Meyerhardt, Jeffrey A , Venook, Alan P. , Ciombor, Kristen K. , Cohen, Stacey A. , Gunn, Andrew, Hubbard, Joleen M. , Jeck, William R. , Miller, Eric D. , Patel, Hitendra, Pedersen, Katrina S. , Saltz, Leonard B. , Schneider, Charles John

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 14, 2022 | Volume: 20 | Issue: 10 | Pages: 1139-1167

10.6004/jnccn.2022.0051 | PMID 36240850 Get It

This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new data supporting the increasingly prominent role of total neoadjuvant therapy, expanded recommendations for short-course radiation therapy techniques, and new recommendations for a “watch-and-wait” nonoperative management technique for patients with cancer that shows a complete response to neoadjuvant therapy. The complete version of the NCCN Guidelines for Rectal Cancer, available online at NCCN.org , covers additional topics including risk assessment, pathology and staging, management of metastatic disease, posttreatment surveillance, treatment of recurrent disease, and survivorship.
Oil Red O Staining of Pulmonary Macrophages in Bronchoalveolar Lavage Specimens Is Not Specific for Vaping-Associated Lung Injury
Thangaiah, Judith Jebastin, Booth, Christine N. , Brainard, Jennifer , Elsheikh, Tarik M. , Ondrejka, Sarah L. , Thilagar, Bright , Mukhopadhyay, Sanjay , Jebastin, Judith A S , Ondrejka, Sarah , Thilagar, Bright P. , Mukhopadhyay, Sanjay , Reynolds, Jordan , Doxtader, Erika

Mayo Clinic

American Journal of Clinical Pathology | October 12, 2022 | Volume: 158 | Issue: 6 | Pages: 723-729

10.1093/ajcp/aqac118 | PMID 36222561 Get It

Abstract Objectives Oil Red O (ORO) positivity in bronchoalveolar lavage (BAL) fluid macrophages in the setting of e-cigarette, or vaping, product use–associated acute lung injury (EVALI) has been frequently requested by clinicians based on rare reports and subsequent US Centers for Disease Control and Prevention guidelines. The aim of this study was to determine the specificity of ORO staining in BAL specimens with disease states other than EVALI. Methods Consecutive BAL specimens (October-December 2019) were stained with ORO. The lipid-laden macrophage index (LLMI) was calculated for each case. Results We studied BAL samples from 50 patients. Indications for BAL were surveillance bronchoscopy for lung transplantation (27/50), suspected infection (12/50), sarcoidosis/suspected sarcoidosis (3/50), nodules or ground-glass opacities (3/50), hemoptysis (2/50), asthma or eosinophilic pneumonia (2/50), and idiopathic pulmonary fibrosis (1/50). ORO staining was seen in BAL fluid macrophages in 45 of 50 cases (focal in 18, moderate in 23, diffuse in 4); LLMI ranged from 0 to 218. Using a threshold of LLMI of 85 or higher as positive, ORO was positive in 7 of 50 (14%) cases (range, 85-218). Conclusions ORO staining in BAL fluid macrophages is not specific for EVALI. Even when an LLMI of 85 or higher is used as a threshold for positivity, ORO positivity occurs in a significant subset of non–vaping-related cases.
Evaluation of Automated Sample Preparation System for Lymph Node Sampling
Duke, Jennifer D. , Hartley, Christopher , Bailey, Morgan , Reid, Michal , Bluestone, Alex, Reisenauer, Janani , Sturgis, Charles D. , Hartley, Christopher P , Bailey, Morgan, Kern, Ryan , Subramanian, Hariharan

Mayo Clinic

No container title available | October 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2142190/v1 Get It

Abstract Purpose: The purpose of this study was to evaluate the feasibility and specimen quality of lymph node biopsies prepared through a novel automated system for automated fixation, drying and staining compared to standard slide preparation method. Methods: We performed a prospective, single-center study of patients undergoing endobronchial ultrasound. Samples were split into conventional standard of care (SOC) slide preparation and preparation using the device (ASP). Pathologists compared the SOC slides to the slides prepared by the automated system and assessed the following metrics: nuclear and cytoplasmic quality, presence of debris/artifact, staining quality, creation of a monolayer, and ease of adequacy/diagnosis assessment. A score between 1 (lowest quality) and 3 (highest quality) was assigned to the above metrics. Results: 60 patients were recruited. One to three lymph nodes were sampled for each patient with a total of 73 samples collected. The mean scores of each assessment category showed no statistical difference between the two preparation techniques except for improved monolayer creation in the ASP samples. All samples showed diagnostic equivalency between the automated slides and conventional slides except for one which was reported to be suspicious on the ASP sample and atypical on the SOC. Conclusion: Study results suggest that slides prepared by the automated system are of adequate quality for adequacy assessment with diagnostic concordance when compared to SOC slides.
Clinical Trial Enrollment, Ineligibility, and Reasons for Decline in Older vs Younger Patients With Cancer in the National Cancer Institute Community Oncology Research Program
Sedrak, Mina S. , Tiwari, Abhay , Mohile, Supriya G. , Dale, William , Sedrak, Mina S. , Ji, Jingran , Le‐Rademacher, Jennifer

Mayo Clinic

JAMA Network Open | October 10, 2022 | Volume: 5 | Issue: 10 | Pages: e2235714

10.1001/jamanetworkopen.2022.35714 | PMID 36215074 Get It

This cross-sectional study assesses differences in clinical trial participation among older vs younger adults with cancer.
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci
DeVries, Amber A , Peng, Pei-Chen , Reyes, Alberto Luiz P., Plummer, Jasmine , Davis, Brian , Chen, Stephanie S., Dezem, Felipe Segato , Antonenkova, Natalia, Beckmann, Matthias W. , Beeghly‐Fadiel, Alicia, Bogdanova, Natalia , Bogdanova-Markov, Nadja, Brenton, James D. , Chang‐Claude, Jenny , Dörk, Thilo , Eccles, Diana M, Fasching, Peter A. , Goode, Ellen L. , Goodman, Marc T. , Group, OPAL Study, Grant, Peter , Nagle, C.A., Chevenix-Trench, G, Bowtell, D, Blomfield, Penny, Davis, Alison , Leung, Yee , Livingstone, Karen, O’Neill, Helen C. , Black, Amanda , Hadley, Alison , Shannon, Colleen, Neesham, Deborah, Otton, Geoffrey, Au‐Yeung, George , Goss, Geraldine , Wain, Gerard, Gard, Grace , Robertson, G S M, Lombard, Janine , Tan, Joanne , McNeilage, Jane, Power, J. , Miller, Jessica A., Lamont, John, Wong, Kit Man , Reid, Kate , Milishkin, L, Buck, Martin , Bunting, Michael W, McNally, Orla , Awad, Reda, Mohan, Rahul , Farrell, Rhonda , McIntosh, Rachel, Rome, Robert, Houghton, R., Hogg, Russell , Land, R., Baron‐Hay, Sally , Paramasivum, S, Pather, Selvan , Hyde, Samuel M. , Salfinger, Stuart , Valmadre, Susan, Jobling, Thomas W., Manolitsas, Tom, Bonaventura, T, Group, AOCS, Bowtell, D, Green, A, Webb, P, Gertig, DM, Moore, S., Hung, Jillian A., Harrap, Karen L. , Sadkowsky, T., Malt, M. , Robertson, R. Paul , Bergh, T. Vanden, Jones, Michelle R. , Nattress, K., Chiew, Yoke-Eng, Stenlake, Annie, Ashover, P., Corrish, T., Jackman, Louisa, Ferguson, Kaltin , Martin, Kara, Martyn, Amanda C. , White, Jonathan, Jayde, V., Bowes, Laura, Mamers, Pamela, Galletta, Laura, Giles, Daniel A., Hendley, Joy , Shirley, H., Ball, C., Young, Christian D. , Viduka, S., Bilic, Sanela , Glavinas, Lydia, Brooks, Jacqueline D., Stuart‐Harris, R., Kirsten, Fred, Rutovitz, J , Clingan, P., Proietto, Anthony , Braye, Stephen, Shannon, J., Bonaventura, T, Begbie, Stephen , Hildebrandt, Michelle A.T., Huff, Chad D. , Huntsman, David G., Kar, Siddhartha , Labrie, Marilyne , Lambrechts, Diether , Le, Nhu D. , May, Taymaa, Menon, Usha , Moysich, Kirsten B. , Odunsi, Kunle , Olsson, Håkan , Pearce, Celeste Leigh , Ramus, Susan J. , Ríboli, Elio , Riggan, Marjorie J. , Romieu, Isabelle , Schildkraut, Joellen M. , Sieh, Weiva , Song, Honglin , Sutphen, Rebecca , Terry, Kathryn L. , Thompson, Pamela J., Titus, Linda , Tworoger, Shelley S. , Nieuwenhuysen, Els Van , Edwards, Digna Velez, Wentzensen, Nicolas , Whittemore, Alice S. , Wu, Anna H. , Freedman, Matthew L., Lawrenson, Kate , Easton, Douglas F. , Gayther, Simon A. , Eccles, Diana , Bowtell, David D.L. , Lambrechts, Diether , Dennis, Joe , Plummer, Jasmine T , Anton-Culver, Hoda , Campbell, Ian G , Chenevix-Trench, Georgia , Eliassen, A Heather , Jensen, Allan , Kar, Siddhartha , Menon, Usha , Riboli, Elio , Sieh, Weiva , Webb, Penelope M , Wentzensen, Nicolas , Wolk, Alicja , Ziogas, Argyrios , Lawrenson, Kate , Jones, Michelle R , Dörk, Thilo , Lambrechts, Diether , Ramus, Susan J , Tworoger, Shelley S , Eccles, Diana , Brenton, James D , Moysich, Kirsten , Lambrechts, Diether , Bogdanova, Natalia V , Bowtell, David D , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Aben, Katja K.H. , Anton‐Culver, Hoda , Beeghly‐Fadiel, Alicia , Berchuck, Andrew , Bützow, Ralf C. , Campbell, Ian , Chenevix‐Trench, Georgia , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Eliassen, A. Heather , Fortner, Renée T. , Giles, Graham G. , Gronwald, Jacek , Group, OPAL Study, Friedländer, Michael , Obermair, Andreas , Nagle, C, Beesley, Vanessa L. , Bowtell, D, Brand, Alison H. , Nicklin, James , Quinn, Michael A. , Williams, M, Hadley, A, Glasgow, A, Garrett, A, Rao, A, Steer, Christopher , Allen, Deborah Emma , Robertson, G, Power, J, Coward, Jermaine , Carter, Jonathan , Lamont, J, Wong, K M, Perrin, Lewis C , Nascimento, M, Buck, M, Harrison, Michelle , Chetty, Naven , Hacker, Neville F. , Harnett, Paul R. , Beale, Philip James , Awad, R, McIntosh, R, Sayer, R, Hogg, R, Hyde, S, Bonaventura, T, Arora, Vivek , Group, AOCS, Bowtell, D, Webb, P, Gertig, Dorota M., Traficante, Nadia , Fereday, Sián , Pandeya, Nirmala , Robertson, R, McKenzie, P, Maidens, J, Sullivan, Helen T. , Alexander, Brian M. , Brown, S, Green, L, Jackman, L, Martyn, A, Ranieri, B, White, J, Giles, D, Alsop, Kathryn , Schmidt, T, Young, C, Tran, H, Rutovitz, J, Glasgow, A, Shannon, J, Bonaventura, T, Stewart, James , Håkansson, Niclas , Hildebrandt, Michelle A.T. , Jensen, Allan , Karlan, Beth Y. , Хуснутдинова, Э. К. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Kupryjańczyk, Jolanta , Lubiński, Jan , Milne, Roger L. , Modugno, Francesmary , Monteiro, Álvaro N.A. , Pejovic, Tanja B. , Sandler, Dale P. , Setiawan, Veronica Wendy , Edwards, Digna R. Velez , Webb, Penelope M. , Wolk, Alicja , Ziogas, Argyrios , Pharoah, Paul D.P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 10, 2022 | Volume: 114 | Issue: 11 | Pages: 1533-1544

10.1093/jnci/djac160 | PMID 36210504 Get It

AbstractBackgroundKnown risk alleles for epithelial ovarian cancer (EOC) account for approximately 40% of the heritability for EOC. Copy number variants (CNVs) have not been investigated as EOC risk alleles in a large population cohort.MethodsSingle nucleotide polymorphism array data from 13 071 EOC cases and 17 306 controls of White European ancestry were used to identify CNVs associated with EOC risk using a rare admixture maximum likelihood test for gene burden and a by-probe ratio test. We performed enrichment analysis of CNVs at known EOC risk loci and functional biofeatures in ovarian cancer–related cell types.ResultsWe identified statistically significant risk associations with CNVs at known EOC risk genes; BRCA1 (PEOC = 1.60E-21; OREOC = 8.24), RAD51C (Phigh-grade serous ovarian cancer [HGSOC] = 5.5E-4; odds ratio [OR]HGSOC = 5.74 del), and BRCA2 (PHGSOC = 7.0E-4; ORHGSOC = 3.31 deletion). Four suggestive associations (P &lt; .001) were identified for rare CNVs. Risk-associated CNVs were enriched (P &lt; .05) at known EOC risk loci identified by genome-wide association study. Noncoding CNVs were enriched in active promoters and insulators in EOC-related cell types.ConclusionsCNVs in BRCA1 have been previously reported in smaller studies, but their observed frequency in this large population-based cohort, along with the CNVs observed at BRCA2 and RAD51C gene loci in EOC cases, suggests that these CNVs are potentially pathogenic and may contribute to the spectrum of disease-causing mutations in these genes. CNVs are likely to occur in a wider set of susceptibility regions, with potential implications for clinical genetic testing and disease prevention.
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.

Mayo Clinic

Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574

10.1097/mpa.0000000000002079 | PMID 36206460 Get It

Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.